LOG IN
SIGN UP
MARKET
DARE
DARE
Dare Bioscience Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
1.150
+0.050
+4.55%
After Hours: 1.160 +0.01 +0.87% 19:24 05/26 EDT
OPEN
1.100
PREV CLOSE
1.100
HIGH
1.170
LOW
1.070
VOLUME
1.04M
TURNOVER
0
52 WEEK HIGH
2.510
52 WEEK LOW
0.9201
MARKET CAP
97.42M
P/E (TTM)
-1.7854
1D
5D
1M
3M
1Y
5Y
Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a virtual fireside chat during the ...
GlobeNewswire · 05/16 12:00
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/12 12:42
Dare Bioscience GAAP EPS of -$0.10 beats by $0.04
Dare Bioscience press release (NASDAQ:DARE): Q1 GAAP EPS of -$0.10 beats by $0.04. $39.3 million in cash and cash equivalents at March 31, 2022
Seekingalpha · 05/12 12:18
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 28.57% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/12 11:15
Dare Bioscience: Q1 Earnings Insights
Dare Bioscience (NASDAQ:DARE) reported its Q1 earnings results on Thursday, May 12, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/12 10:19
BRIEF-Daré Bioscience Reports First Quarter 2022 Financial Results And Provides A Company Update
reuters.com · 05/12 10:11
Dare Bioscience Q1 EPS $(0.10) Beats $(0.14) Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 41.18 percent increase over losses of $(0.17) per share from
Benzinga · 05/12 10:07
-- Earnings Flash (DARE) DARE BIOSCIENCE Reports Q1 Loss $-0.10
MT Newswires · 05/12 06:15
No Data
Learn about the latest financial forecast of DARE. Analyze the recent business situations of Dare Bioscience Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 5 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average DARE stock price target is 7.20 with a high estimate of 17.00 and a low estimate of 3.000.
Current 1.150
EPS
Actual
Estimate
-0.20-0.18-0.16-0.14
Institutional Holdings
Institutions: 39
Institutional Holdings: 7.20M
% Owned: 8.50%
Shares Outstanding: 84.71M
TypeInstitutionsShares
Increased
14
1.58M
New
9
1.60M
Decreased
5
227.82K
Sold Out
7
586.07K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
William Rastetter
President/Chief Executive Officer/Secretary/Director
Sabrina Johnson
Chief Financial Officer
Lisa Walters-Hoffert
Other
John Fair
Independent Director
Cheryl Blanchard
Independent Director
Jessica Grossman
Independent Director
Susan Kelley
Independent Director
Gregory Matz
Independent Director
Sophia Ononye-Onyia
Independent Director
Robin Steele
No Data
No Data
About DARE
Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing products for women’s health. Its portfolio of differentiated therapies expands treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Its product pipeline includes three product candidates in advanced stages of clinical development, three in Phase I clinical development and three in pre-clinical stage development. The product candidates in its pipeline include DARE-BV1, Ovaprene, Sildenafil Cream, 3.6%, DARE-HRT1, DARE-FRT1, DARE-VVA1, DARE-LARC1, ORB-204 and ORB-214, and DARE-RH1. DARE-BV1 is focused on the treatment for bacterial vaginosis. Ovaprene is designed to provide multiple weeks of contraceptive protection and Sildenafil Cream, 3.6% is for the treatment of female sexual arousal disorders are under advanced stages of clinical development.
Webull offers kinds of Dare Bioscience Inc stock information, including NASDAQ:DARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DARE stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading DARE stock methods without spending real money on the virtual paper trading platform.